3 Under-the-Radar Biotech Stocks You Need to Watch in 2014
Nektar Therapeutics, Omeros, and Spectrum Pharmaceuticals all face off with regulators in key decision dates for their developmental drugs later this year
Can Nektar Therapeutics Beat Pfizer Inc.?
In addition to Remoxy, Pfizer has an in-house formulation of abuse-resistant oxycodone in late stage trials. Could an all new opioid from Nektar Therapeutics upend both programs?